Here, we report primary efficacy and safety data from an independent analysis in Chinese patients in IMpower132 evaluating atezolizumab plus pemetrexed and cisplatin for first‐line treatment of non‐squamous EGFR‐ or ALK‐negative NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.